EUVIMEDEUVIMED entdecken
Crossref

Tapinarof, a Novel, First-in-Class, Topical Therapeutic Aryl Hydrocarbon Receptor Agonist for the Management of Psoriasis

Margaret Bobonich, Joe Gorelick, Lakshi Aldredge, Matthew J Bruno, Douglas DiRuggiero, George Martin, Anna M Tallman, Linda Stein Gold

Journal of Drugs in Dermatology · 2023

DOI: 10.36849/jdd.7317 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Drugs in Dermatology, 2023. Verfasst von Margaret Bobonich und 7 weiteren Autor:innen. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Psoriasis. Die Arbeit wurde bisher 14-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Topical treatments remain the foundation of psoriasis management. Tapinarof (VTAMA®; Dermavant Sciences, Inc.) is a first-in-class, non-steroidal, topical, aryl hydrocarbon receptor (AhR) agonist approved by the US Food and Drug Administration for the treatment of plaque psoriasis in adults and is under investigation for the treatment of psoriasis in children, and atopic dermatitis in adults and children down to 2 years old. Here, we review the mechanism of action of tapinarof and the PSOARING phase 3 trial program in mild to severe psoriasis. AhR is a ligand-dependent transcription factor involved in maintaining skin homeostasis. Tapinarof specifically binds to AhR to decrease proinflammatory cytokines, decrease oxidative stress, and promote skin barrier normalization. In two identical, randomized, 12-week pivotal phase 3 trials, PSOARING 1 and 2, tapinarof cream 1% once daily (QD) demonstrated significant efficacy versus vehicle and was well tolerated in adults with mild to severe psoriasis. In the PSOARING 3 long-term extension trial of repeated, intermittent tapinarof cream in eligible patients completing the pivotal trials, a high rate of complete disease clearance (40.9%) and a remittive effect of approximately 4 months off therapy were demonstrated over 52 weeks, with no tachyphylaxis. The most common adverse event, folliculitis, was mostly mild or moderate and resulted in a low trial discontinuation rate in PSOARING 1 and 2 (≤1.8%). Tapinarof cream 1% QD provides a novel, non-steroidal, topical treatment option for patients with psoriasis and is highly effective and well tolerated with long-term use including when applied to sensitive and intertriginous skin. Bobonich M, Gorelick J, Aldredge L, et al. Tapinarof, a novel, first-in-class, topical therapeutic aryl hydrocarbon receptor agonist for the management of psoriasis. J Drugs Dermatol. 2023;22(8):779-784. doi:10.36849/JDD.7317.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicPsoriasisHumansEmollientsReceptors, Aryl HydrocarbonSkinTreatment OutcomeClinical Trials, Phase III as TopicRandomized Controlled Trials as TopicResorcinolsStilbenes

Substanzen

EmollientsReceptors, Aryl HydrocarbontapinarofResorcinolsStilbenes

Zitieren

APA

Bobonich, M., Gorelick, J., Aldredge, L., Bruno, M. J., DiRuggiero, D., Martin, G., Tallman, A. M., & Gold, L. S. (2023). Tapinarof, a Novel, First-in-Class, Topical Therapeutic Aryl Hydrocarbon Receptor Agonist for the Management of Psoriasis. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.7317

Vancouver

Bobonich M, Gorelick J, Aldredge L, Bruno MJ, DiRuggiero D, Martin G, et al. Tapinarof, a Novel, First-in-Class, Topical Therapeutic Aryl Hydrocarbon Receptor Agonist for the Management of Psoriasis. Journal of Drugs in Dermatology. 2023. doi:10.36849/jdd.7317

BibTeX
@article{Bobonich2023,
  author = {Bobonich, Margaret and Gorelick, Joe and Aldredge, Lakshi and Bruno, Matthew J and DiRuggiero, Douglas and Martin, George and Tallman, Anna M and Gold, Linda Stein},
  title = {Tapinarof, a Novel, First-in-Class, Topical Therapeutic Aryl Hydrocarbon Receptor Agonist for the Management of Psoriasis},
  journal = {Journal of Drugs in Dermatology},
  year = {2023},
  doi = {10.36849/jdd.7317}
}
Kostenlos starten →